Neurological Disorders
Neuroscios
Expert CRO in Neurological Disorders
Neurological disorders affect millions worldwide, causing devastating health challenges for patients and placing a significant burden on healthcare systems. From neurodegenerative diseases to rare CNS disorders, the complexity of these conditions demands innovative solutions.
At Sanos, we are committed to driving progress in neurological clinical research. Our expertise in clinical trial design, patient recruitment, and advanced biomarker analysis allows us to accelerate drug development and improve treatment options. Together with our neurology-focused CRO, Neuroscios, we provide a full suite of services tailored to the intricacies of neurological clinical research.
Our Expertise
At Neuroscios, we bring deep expertise in neurological disorders, with a particular focus on Alzheimer’s disease and neurodegeneration. Our scientific and operational leadership in neurology clinical trials ensures high-quality, data-driven research that accelerates treatment development.
Alzheimer’s Disease
Neuroscios specializes in biomarker-driven trials, early detection strategies, and disease-modifying therapies for Alzheimer’s disease. Our research advances innovative approaches to delay or prevent disease progression.
Scientific Leadership
Our team of neurology specialists brings decades of experience in neurological clinical research, ensuring scientific expertise and operational excellence in every trial.
Publications
We have a proven track record of successful trials in neurology, delivering high-quality data and advancing innovative therapies.
Key Indications
- Alzheimer’s Disease
- Parkinson’s Disease
- ALS
- Orphan Neurodegenerative Disorders
- Cerebrovascular Diseases
Explore Neuroscios
Clinical Research & Trial Capabilities
Neurological disorders require specialized trial designs to address complex disease mechanisms, biomarker-driven endpoints, and patient variability. At Sanos and Neuroscios, we provide full-service clinical trial expertise, ensuring high-quality execution and regulatory success.
- Scientific Expertise
- Tailored Study Design
- Patient Recruitment & Site Network
- Biomarker & Imaging Integration
- Seamless Trial Execution
Expertise in Neurological Disorders
We’re specialized in Alzheimer’s disease, Parkinson’s disease, ALS, orphan neurodegenerative disorders, and cerebrovascular disease. Our deep understanding of CNS disease mechanisms ensures optimized trial design and execution.
Tailored Study Design
We provide end-to-end protocol development, endpoint selection, and regulatory submissions (IND/CTA) to meet FDA, EMA, and global compliance requirements. Our expertise ensures trials are structured for efficiency and scientific integrity.
Patient Recruitment & Site Network
With access to a global network of neurology research sites, patient registries, and Key Opinion Leaders (KOLs), we facilitate rapid enrollment, patient retention, and high-quality data collection.
Biomarker & Imaging Integration
We leverage fluid biomarkers, neuroimaging (MRI, PET), digital endpoints, and AI-driven analytics to enhance study precision, ensuring better patient stratification and trial success.
Seamless Trial Execution
From early-phase trials to late-stage studies, we manage project oversight, site monitoring, data analysis, and pharmacovigilance, ensuring efficient trial conduct and regulatory success.
Decades of expertise in neurological clinical research.
Advancing treatments through dedicated studies.
Phase I Trials
Driving early-stage innovation in neurology.
Neuroscios
At Neuroscios, we focus exclusively on neurological clinical research – combining scientific depth with operational expertise. We are experts in neurology, and pioneering advancements in Alzheimer’s and CNS disorders with deep scientific insight.
Neuroscios
Partner with Us
“Neurology trials are complex and getting them right takes real expertise. At Neuroscios, we’ve spent decades working in neurological clinical research, refining trial designs, and building deep biomarker knowledge. Our team knows how to navigate the challenges of neurodegenerative and psychiatric studies, delivering high-quality data that stands up to regulatory scrutiny.”
Manfred Windisch, PhD, VP and Founder of Neuroscios